Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Illig

Showing results (101-110 of 101) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 101 results.
Molecular Cancer Therapeutics|November 6, 2009
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemiaCarl L Manthey, Dana L Johnson, Carl R Illig, et al.
Pageof 11

Showing results (101-110 of 101) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 101 results.
Molecular Cancer Therapeutics|November 6, 2009
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemiaCarl L Manthey, Dana L Johnson, Carl R Illig, et al.
Pageof 11